Nuvalent (NASDAQ:NUVL) Downgraded to Hold Rating by Canaccord Genuity Group

Canaccord Genuity Group downgraded shares of Nuvalent (NASDAQ:NUVL) from a strong-buy rating to a hold rating in a research report sent to investors on Tuesday,Zacks.com reports.

Other equities research analysts have also issued reports about the stock. Cantor Fitzgerald lowered shares of Nuvalent from an “overweight” rating to a “neutral” rating in a report on Tuesday. Robert W. Baird set a $122.85 target price on shares of Nuvalent in a research note on Tuesday. Piper Sandler lowered shares of Nuvalent from an “overweight” rating to a “neutral” rating and set a $124.00 target price on the stock. in a research note on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvalent in a research note on Tuesday, April 21st. Finally, Lifesci Capital lowered shares of Nuvalent from an “outperform” rating to a “hold” rating and set a $124.00 target price on the stock. in a research note on Tuesday. Five analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $131.15.

Nuvalent Stock Performance

NASDAQ:NUVL opened at $123.35 on Tuesday. Nuvalent has a one year low of $71.13 and a one year high of $123.62. The firm has a market cap of $9.74 billion, a price-to-earnings ratio of -20.35 and a beta of 1.15. The firm’s fifty day moving average is $103.44 and its two-hundred day moving average is $103.19.

Nuvalent (NASDAQ:NUVL) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.04). During the same quarter in the prior year, the firm earned ($1.18) EPS. As a group, equities research analysts predict that Nuvalent will post -5.74 earnings per share for the current fiscal year.

Insider Activity at Nuvalent

In other Nuvalent news, insider Henry E. Pelish sold 3,093 shares of the stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $104.48, for a total value of $323,156.64. Following the completion of the sale, the insider owned 65,604 shares in the company, valued at approximately $6,854,305.92. This represents a 4.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO James Richard Porter sold 30,000 shares of the stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $88.53, for a total transaction of $2,655,900.00. Following the completion of the sale, the chief executive officer owned 324,879 shares of the company’s stock, valued at approximately $28,761,537.87. The trade was a 8.45% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 126,953 shares of company stock worth $12,612,264 in the last quarter. Company insiders own 5.02% of the company’s stock.

Institutional Trading of Nuvalent

A number of hedge funds have recently bought and sold shares of NUVL. GAMMA Investing LLC raised its holdings in Nuvalent by 47.6% in the 4th quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock valued at $34,000 after acquiring an additional 108 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in Nuvalent by 141.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 333 shares of the company’s stock valued at $34,000 after acquiring an additional 195 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in Nuvalent in the 3rd quarter valued at about $38,000. NBC Securities Inc. acquired a new stake in Nuvalent in the 4th quarter valued at about $125,000. Finally, KBC Group NV raised its holdings in Nuvalent by 24.1% in the 4th quarter. KBC Group NV now owns 1,527 shares of the company’s stock valued at $154,000 after acquiring an additional 297 shares during the last quarter. Institutional investors and hedge funds own 97.26% of the company’s stock.

Nuvalent News Roundup

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: GSK’s $10.6 billion all-cash acquisition offer gives Nuvalent shareholders a clear exit value at $124.00 per share, which is the biggest reason the stock has increased. Reuters article on GSK deal
• Positive Sentiment: Market commentary says the deal makes strategic sense for GSK because Nuvalent adds a late-stage oncology pipeline, supporting confidence that the transaction is credible and financially meaningful. MarketBeat analysis of the acquisition
• Neutral Sentiment: Several shareholder law firms have launched investigations into whether the sale process and price are fair, which could create headline noise but does not change the announced terms. Business Wire article on investigation
• Neutral Sentiment: Analyst downgrades followed the takeover news, but their revised price targets remain close to the deal value, so these moves are unlikely to outweigh the acquisition catalyst. Analyst downgrade coverage
• Negative Sentiment: CEO James Richard Porter sold 30,000 shares, a modest negative sentiment signal that may reinforce the view that insiders have been reducing exposure ahead of the transaction. SEC insider filing

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.